Plk1-targeted therapies in TP53- or RAS-mutated cancer

克拉斯 PLK1 Polo样激酶 癌症研究 癌症 激酶 胞质分裂 有丝分裂 靶向治疗 医学 生物 遗传学 细胞 结直肠癌 细胞分裂 细胞周期
作者
Hyungshin Yim,Raymond L. Erikson
出处
期刊:Mutation Research-reviews in Mutation Research [Elsevier]
卷期号:761: 31-39 被引量:38
标识
DOI:10.1016/j.mrrev.2014.02.005
摘要

Despite advances in treatment, prognosis for many types of carcinoma remains poor. Polo-like kinase 1 (Plk1) has been explored as a target for the development of anticancer drugs. As a mitotic master Ser/Thr kinase, Plk1 is involved in centrosomal maturation, microtubule nucleation, chromosomal segregation, and cytokinesis. Additional functions in interphase and in response to DNA damage have been revealed. The multiple locations of Plk1 correspond to distinct functions, mediated by phosphorylation of multiple substrates. Since it is highly expressed in several carcinomas, and expression of Plk1 is inversely correlated with the survival rate of patients in non-small cell lung, head and neck, and esophageal cancer, Plk1 is recognized as a valid prognostic marker. Connections between Plk1 and p53 or KRAS in carcinoma provide a rationale and several possible routes to the development of therapies. Tumors with both p53-deficiency and high Plk1 expression may be particularly sensitive to Plk1 inhibitors, although some controversial data exist. In KRAS-mutant cancers, on the other hand, Plk1 may be essential for tumor cell survival, but detailed studies as to whether Plk1 inhibitors are more effective in KRAS-mutant cancers must be performed in order to determine whether this is the case. Here, we present evidence for Plk1 as a prognostic marker and potentially effective target for the treatment of patients with carcinoma, to demonstrate the value of Plk1 as a target for the development of cancer treatment, especially for patients with solid tumors. In addition, the effects of Plk1 inhibition in p53- or KRAS-mutated cancer are discussed with respect to clinical implications. Structural specifics of Plk1 are presented, as well as current strategies for discovering new Plk1 inhibitors by targeting the conserved ATP binding site or polo-box domain of Plk1, in order to develop Plk1-specific anticancer drugs.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
慕问旋完成签到,获得积分20
2秒前
Hello应助唠叨的映冬采纳,获得10
2秒前
Srui完成签到,获得积分10
3秒前
qiaobaqiao完成签到 ,获得积分10
4秒前
芒果布丁发布了新的文献求助10
6秒前
7秒前
8秒前
EVAN完成签到,获得积分10
9秒前
11秒前
科研通AI2S应助doing采纳,获得10
11秒前
12秒前
14秒前
云风完成签到,获得积分20
15秒前
姚美阁发布了新的文献求助10
15秒前
17秒前
123发布了新的文献求助10
18秒前
勤恳的磬发布了新的文献求助10
18秒前
lrq完成签到,获得积分10
19秒前
20秒前
CodeCraft应助芒果布丁采纳,获得10
20秒前
小高同学发布了新的文献求助10
21秒前
23秒前
CipherSage应助Billy采纳,获得10
23秒前
云风发布了新的文献求助10
23秒前
西瓜完成签到 ,获得积分10
23秒前
29秒前
30秒前
SciGPT应助科研民工花儿采纳,获得30
30秒前
Singularity应助GD采纳,获得10
30秒前
33秒前
Ting完成签到 ,获得积分10
34秒前
35秒前
明天过后完成签到,获得积分10
37秒前
汉堡包应助拥抱爱莉采纳,获得10
38秒前
大意的如雪完成签到,获得积分10
39秒前
Hysen_L完成签到,获得积分10
40秒前
hhhs发布了新的文献求助30
40秒前
43秒前
44秒前
Pauline完成签到,获得积分10
45秒前
高分求助中
Sustainability in Tides Chemistry 2800
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Bayesian Models of Cognition:Reverse Engineering the Mind 888
Le dégorgement réflexe des Acridiens 800
Defense against predation 800
Very-high-order BVD Schemes Using β-variable THINC Method 568
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3136176
求助须知:如何正确求助?哪些是违规求助? 2787079
关于积分的说明 7780454
捐赠科研通 2443217
什么是DOI,文献DOI怎么找? 1298964
科研通“疑难数据库(出版商)”最低求助积分说明 625294
版权声明 600870